Sweden opts for coronavirus protein vaccine instead of mRNA From the 2027/2028 season onwards, Sweden will use only a protein-based coronavirus vaccine for its national vaccination campaign. It is the first country in the world to say goodbye to the mRNA vaccines. Difference in technology Nuvaxovid is a classic protein vaccine. It contains a ready-made piece of the virus (the spike protein), produced using recombinant technology (a molecular method in which DNA from different organisms is combined in the laboratory and placed into a host cell (such as a bacterium or yeast) to allow it to multiply or produce proteins) and provided with an adjuvant (an excipient that stimulates and strengthens the body's immune response to the antigen, so that the vaccine works better). The body is presented with this protein directly to build an immune response. This differs from mRNA vaccines (such as Comirnaty from Pfizer/BioNTech), where the body's cells must produce the spike protein themselves after receiving the mRNA instruction. This process carries the risk of autoimmune reactions, especially because these products do not remain at the injection site but can spread throughout the body. Furthermore, the quantity and duration of spike protein production are not defined in the mRNA technique. In addition, the lipid coating of the mRNA vaccines is very reactive. All in all, this leads to a disproportionate number of side effects, some very serious and resulting in death (1-3). Sweden chose its own path during the coronavirus years by not enforcing lockdowns or school closures. Although there was much criticism of this at the time, the Swedish approach was later appreciated ( De Morgen, 25 December 2023 ). With the decision to phase out coronavirus mRNA vaccines, Sweden appears set to play a pioneering role once again. The Doctors' Collective, together with European partners, has been advocating for the cessation of mRNA vaccinations for quite some time. Sources: Sanofi press release (April 21, 2026), LäkemedelsVärlden report and Läkemedelsmarknaden report regarding the tender. References Cappelletti-Montano B, Demuru G, Laconi E and Musio M (2023) A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults. Front. Public Health 11:1145645. doi: 10.3389/fpubh.2023.1145645 Szebeni, J. Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges. Pharmaceutics 2025, 17, 450. Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022 Sep 22;40(40):5798-5805. doi: 10.1016/j.vaccine.2022.08.036. Epub 2022 Aug 31. PMID: 36055877; PMCID: PMC9428332. artsencollectief.nl/zweden-k…